Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

[1]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[2]  M. Pirmohamed,et al.  A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions , 2016, PharmacoEconomics.

[3]  E. Antman,et al.  Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.

[4]  G. Lip,et al.  Stroke prevention in atrial fibrillation: a systematic review. , 2015, JAMA.

[5]  A. de Boer,et al.  Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. , 2015, Pharmacogenomics.

[6]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[7]  M Pirmohamed,et al.  Cost‐Effectiveness of Pharmacogenetics‐Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation , 2014, Clinical pharmacology and therapeutics.

[8]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[9]  Rita Barallon,et al.  A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.

[10]  Ramon Luengo-Fernandez,et al.  Population-Based Study of Acute- and Long-Term Care Costs after Stroke in Patients with AF , 2013, International journal of stroke : official journal of the International Stroke Society.

[11]  A. de Boer,et al.  Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. , 2013, Pharmacogenomics.

[12]  S. Yusuf,et al.  Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial , 2012, Circulation.

[13]  L. Levin,et al.  Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. , 2012, Pharmacogenomics.

[14]  A. H. Maitland‐van der Zee,et al.  Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[15]  M. Pirmohamed,et al.  A Proposal for an Individualized Pharmacogenetics‐Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy , 2011, Clinical pharmacology and therapeutics.

[16]  M. Rosenqvist,et al.  Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. , 2011, European heart journal.

[17]  G. Lip,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[18]  B. Gage,et al.  Abstract 16179: Cost-effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010 .

[19]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[20]  J. Darbà,et al.  A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. , 2010, Pharmacogenomics.

[21]  R L Berg,et al.  Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.

[22]  Marc S. Williams,et al.  A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing , 2010, PharmacoEconomics.

[23]  H. Diener,et al.  Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[25]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[26]  A. Forster,et al.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis , 2008, Canadian Medical Association Journal.

[27]  S. Bryan,et al.  A multinational investigation of time and traveling costs in attending anticoagulation clinics. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[29]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[30]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[31]  Vahram Ghushchyan,et al.  A National Catalog of Preference-Based Scores for Chronic Conditions in the United States , 2005, Medical care.

[32]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[33]  B. Gage,et al.  Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. , 2005, JAMA.

[34]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[35]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[36]  A. de Boer,et al.  Pharmacogenetics of oral anticoagulant therapy. , 2010, Current pharmaceutical design.

[37]  D K Owens,et al.  The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. , 1996, Archives of internal medicine.